

ECTRIMS Focused Workshop 2025

20-21 March 2025 | Malta

The era of checkpoint inhibitors and CAR-T cell therapies: what the neurologists need to know

THURSDAY, 20 MARCH 2025

- | | |
|----------------------|---|
| 08.45 | Welcome and Introduction
<i>B. Stankoff (Paris, FR),
M. Inglese (Genoa, IT),
J. Dalmau (Barcelona, ES)</i> |
| 09.00 - 10.10 | Session 1: Describing mechanisms of action of immune and CAR-T therapies
<i>Chairs: J. Dalmau (Barcelona, ES) S. Zamvil (San Francisco, US)</i> |
| 09.00 | Immune check-point inhibitors (anti-CTLA-4, anti PDL-1, anti-PD-1)
<i>E. Marcenaro (Genoa, IT)</i> |
| 09.20 | Current CAR-T cell therapies
<i>M. Juan (Barcelona, ES)</i> |
| 09.40 | Novel CAR technologies
<i>M. Simic (San Francisco, US)</i> |
| 10.00 - 10.30 | Round table discussion |
| 10.30 - 11.00 | Coffee Break |

- 11.00 - 13.10** **Session 2: Describing indications of immune and CAR-T therapies in cancer and autoimmune diseases**
*Chairs: H.-P. Hartung (Düsseldorf, DE),
M. Tintoré (Barcelona, ES),*
- 11.00 CAR-T cell therapies in cancer
L. Perez-Amill (Barcelona, ES)
- 11.20 CAR-T cell therapies in autoimmune diseases
D. J. Baker (Pennsylvania, US)
- 11.40 CAR-T cell therapies in Myasthenia gravis and NMOSD
R. Gold (Bochum, DE)
- 12.00 CAR-T cell therapies in MS: from case series to clinical trials
S. Zamvil (San Francisco, US)
- 12.20 CAR T-cells therapies in children
Y. Hacohen (London, UK)
- 12.40 - 13.10** **Round table discussion**
- 13.10 - 14.10** **Lunch Break**
- 14.10 - 15.40** **Session 3: neurological complications of check-point inhibitors and CAR-T therapies**
Chairs: B. Stankoff (Paris, FR), H. Wiendl (Freiburg, DE)
- 14.10 CNS complications of check-point inhibitors
B. Joubert (Lyon, FR)
- 14.30 PNS complications of check-point inhibitors
E. Martinez-Hernandez (Barcelona, ES)
- 14.50 Neurological complications of CAR-T cell therapy
F. Fischbach (Hamburg, DE)
- 15.10 - 15.40** **Round table discussion**
- 15.40 - 16.10** **Coffee Break**

16.10 – 17.40 Session 4: Management and Treatment of complications of immune and CAR-T cell therapies

Chairs: M. Inglese (Genoa, IT), B. Willekens (Antwerpen, BE)

16.10 Treating neurological complications of check-point inhibitors (anti-CTLA-4, anti PDL-1 anti-PD-1)

R. Velasco (Barcelona, ES)

16.30 Treating neurological complications of CAR-T cell therapies

H.-P. Hartung (Düsseldorf, DE)

16.50 Neuroimaging of neurological complications of immune checkpoint inhibitors and CAR-T cell therapy

A. Lasocki (Melbourne, AU)

17.10 - 17.40 Round table discussion

19.10 Focused Workshop Dinner

FRIDAY, 21 MARCH 2025

- 08.30 - 09.30** **Session 5: How to predict toxicity and neurological complications: the role of biomarkers**
Chairs: O. Ciccarelli (London, UK), A. Haghikia (Hannover, DE)
- 08.30 Immune and clinical monitoring post check-point inhibitors and CAR-T cell therapy in haematological malignancies
S. Pagliuca (Nancy, FR)
- 09.00 Immune and clinical monitoring post CAR-T cell therapy in autoimmune diseases
M. T. Cencioni (London, UK)
- 09.30 - 10.00** **Round table discussion**
- 10.00 - 10.30** **Coffee Break**
- 10.30 - 11.30** **Working Groups:**
- Group 1: Biomarkers for check-point inhibitors complications**
*B. Joubert (Lyon, FR); J. Sastre-Garriga (Barcelona, ES),
G. Bsteh (Vienna, AT)*
- Group 2: Biomarkers for CAR-T cell therapy complications**
*H. Wiendl (Freiburg, DE), S. Mariotto (Verona, IT)
G. Androdias (Lyon, FR)*
- 11.30** Feedback from working group chairs (10 min each group), concluding remarks and future directions (10 min Chairs)
- As of 12.30** **Lunch and individual departure**